Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: A study of the Hoosier Oncology Group
| Autor: | Daniel Hood, Christie M. Orschell, Sarah C. Nabinger, Carol H. Sampson, Edward M. Chan, Rebecca J. Chan, Kristopher J. Kohlbacher, Evan S. West, Chua Lin Hui, Larry D. Cripe, Zhenyun Yang, Artur Plett, Hamid Sayar, Amanda Walter, Jingwei Wu, Zhangsheng Yu |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Oncology Antimetabolites Antineoplastic Cancer Research medicine.medical_specialty Methyltransferase Anemia Population Azacitidine bcl-X Protein Apoptosis Lower risk hemic and lymphatic diseases Internal medicine medicine Humans Erythropoiesis education Erythropoietin Aged Aged 80 and over Erythroid Precursor Cells education.field_of_study business.industry Myelodysplastic syndromes Hematology Middle Aged Flow Cytometry Prognosis medicine.disease Myelodysplastic Syndromes Female business medicine.drug |
| Zdroj: | Leukemia Research. 35:1108-1110 |
| ISSN: | 0145-2126 |
| Popis: | Prolonged administration of methyl transferase inhibitors may increase response rates in myelodysplastic syndromes (MDS). Fourteen MDS patients with anemia and less than 10% marrow blasts received azacitidine 50 mg/m(2) thrice weekly for 2 weeks every 4 weeks; 7 also received weekly erythropoietin. The response rate of 43% did not improve the rates reported with other azacitidine administration schedules, so the study was closed. A decreased apoptosis of primitive erythroid progenitors and increased expression of BclX(L) was observed with treatment in responding patients compared to non-responders. Azacitidine may modulate BclX(L) and improve erythropoiesis through reduction of apoptosis in primitive erythroid progenitor population in MDS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect